JP3638570B2 - Containerized tea beverage - Google Patents

Containerized tea beverage Download PDF

Info

Publication number
JP3638570B2
JP3638570B2 JP2002143743A JP2002143743A JP3638570B2 JP 3638570 B2 JP3638570 B2 JP 3638570B2 JP 2002143743 A JP2002143743 A JP 2002143743A JP 2002143743 A JP2002143743 A JP 2002143743A JP 3638570 B2 JP3638570 B2 JP 3638570B2
Authority
JP
Japan
Prior art keywords
catechins
black tea
gallate
acid
tea beverage
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2002143743A
Other languages
Japanese (ja)
Other versions
JP2003333989A (en
Inventor
久雄 大村
千明 阿部
祐司 松井
潔 片岡
直樹 細谷
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kao Corp
Original Assignee
Kao Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kao Corp filed Critical Kao Corp
Priority to JP2002143743A priority Critical patent/JP3638570B2/en
Publication of JP2003333989A publication Critical patent/JP2003333989A/en
Application granted granted Critical
Publication of JP3638570B2 publication Critical patent/JP3638570B2/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Description

【0001】
【発明の属する技術分野】
本発明は非重合体カテキン類の血中移行率の高くかつ味の良好な容器詰紅茶飲料に関する。
【0002】
【従来の技術】
現在、缶飲料やインスタント飲料を始めとして茶葉を原料として含む食品が大量に販売されている。また一方で緑茶、紅茶、烏龍茶などの茶飲料に含まれている非重合体カテキン類が、コレステロール上昇抑制作用(特開昭60−156614号公報)、α−アミラーゼ活性阻害作用(特開平3−133928号公報)、血糖上昇阻害作用(特開平4−253918号公報)、動脈硬化防止作用(特開平4−352726号公報)、抗酸化作用(特公平1−44234号公報)、抗菌作用(特開平2−276562号公報)、抗潰瘍作用(特開昭63−277628号公報)や突然変異抑制作用等の生理作用を有すると報告されている。
【0003】
これらの非重合体カテキン類の生理作用を、より効果的に発現させるためには、非重合体カテキン類の摂取量を増やすことが必要である。多量の非重合体カテキン類を摂取するためには、摂取の容易な飲料形態が、嗜好性、市場性から望ましい。
【0004】
しかし、経口的に摂取された非重合体カテキン類は、ごく一部の非重合体カテキン類が消化管から吸収され、その一部は粘膜上皮細胞内により抱合反応を受け、門脈血を経て肝臓に運ばれ、そこで更に抱合され一部は遊離型のまま血流に入り末梢組織に移行するが、一部は肝臓から分泌される胆汁液に含まれた形で十二指腸に注入され腸肝循環するとともに、腎臓を経て最終的に尿中に排泄してしまうことが知られている(化学と生物,vol38,No2,104〜114頁,2000年)。このように飲料中の非重合体カテキン類含量を単に高めただけでは、その血中移行率は必ずしも高くならない。
【0005】
【発明が解決しようとする課題】
本発明の目的は、飲用した非重合体カテキン類の血中への移行量を高め、体内利用度が向上し、かつ味の良好な紅茶飲料を提供することにある。
【0006】
【課題を解決するための手段】
そこで本発明者は、種々の紅茶飲料を製造し、非重合体カテキン類組成と血中移行率との関係について検討したところ、高濃度で非重合体カテキン類を含有する容器詰紅茶飲料中の非重合体カテキン類中のエピ体カテキン類比率を制御することにより、同一の非重合体カテキン類濃度でありながら飲用した時の非重合体カテキン類の血液中への移行量を更に増加できることを見出した。
【0007】
すなわち、本発明は1)次の非重合体成分(A)及び(B):
A)非エピ体カテキン類(カテキン+ガロカテキン+カテキンガレート+ガロカテキンガレート)
(B)エピ体カテキン類(エピカテキン+エピガロカテキン+エピカテキンガレート+エピガロカテキンガレート)
のカテキン類を溶解して含有し、当該成分(A)及び(B)の含有量が次の(イ)及び(ロ)、
(イ)(A)+(B)=0.1〜0.3重量%
(ロ)(B)/[(A)+(B)]=0.5〜0.95
を満たし、
2)ヒドロキシカルボン酸又はそれらの塩類 0.005〜10.0重量%を含有し、
3)pHが3.0〜4.7である、茶抽出物を添加した容器詰紅茶飲料を提供するものである。
【0008】
【発明の実施の形態】
本発明でいう非重合体カテキン類[(A)+(B)]とは、カテキン、ガロカテキン、カテキンガレート及びガロカテキンガレートの非エピ体カテキン類(A)と、エピカテキン、エピガロカテキン、エピカテキンガレート及びエピガロカテキンガレートのエピ体カテキン類(B)とを併せた総称である。
【0009】
本発明において非重合体カテキン類は、水中に溶解した非重合体カテキン類である。溶解していない場合、物理的に体内吸収性が低下するので、非重合体カテキン類は溶解しているのが好ましい。
【0010】
本発明紅茶飲料中に非重合体カテキン類[(A)+(B)]は0.1〜0.3重量%含有するが、好ましくは0.1〜0.25重量%、更に好ましくは0.1〜0.2重量%である。非重合体カテキン類濃度が、0.1重量%未満では十分な生理効果が得られず、0.3重量%を超えると風味が好ましくなくなる。
【0011】
また、本発明紅茶飲料における非重合体カテキン類中にはエピ体カテキン類(B)が、重量比[(B)/(A)+(B)]で0.5〜0.95、好ましくは0.6〜 0.9、更に好ましくは0.66〜0.9含まれる。この比率が0.5未満では、摂取された非重合体カテキン類の血中移行率が十分でない。
【0012】
非重合体カテキン類[(A)+(B)]中のエピガロカテキンガレート、ガロカテキンガレート、エピカテキンガレート及びカテキンガレート(ガレート体)は、生理活性が強いといわれている。ここでエピガロカテキンガレート、ガロカテキンガレート、エピカテキンガレート及びカテキンガレートは1種以上含有するが、通常は全て含有される。ここでカテキン類[(A)+(B)]中のガレート体の重量%をガレート体率と呼ぶ。
本発明においては、このガレート体率が45重量%以上、より好ましくは46〜98重量%であるのが、飲用したときの血液中への非重合体カテキン類の移行量が大きくなり、生理効果が強く、健康紅茶飲料として一層好ましいものになる。
【0013】
本発明の容器詰紅茶飲料のpHは25℃で3.0〜4.7、特に3.3〜4.5 とするのが、味及び非重合体カテキン類の化学的安定性の点で好ましい。非重合カテキン類は苦味・渋味を有するが、そこに酸味成分が配合されるとその苦味・渋味が緩和される。また、pHが低くなることで加熱及び殺菌によるエピ体カテキン類の異性化(非エピ化)が抑制され、血中移行量が増加する。
【0014】
本発明の紅茶飲料には、ヒドロキシカルボン酸又はそれらの塩類を配合すると、呈味が改善できると共に、pHを調整できることから好ましい。ヒドロキシカルボン酸としては、クエン酸、コハク酸、イタコン酸、リンゴ酸及び酒石酸から選ばれる一種以上が、呈味の観点から好ましい。ここで塩類としては、ナトリウム塩、カリウム塩などのアルカリ金属塩、カルシウム塩、マグネシウム塩等のアルカリ土類金属塩が挙げられる。また、それらのヒドロキシカルボン酸又はその塩類を含有する果汁類、果汁濃縮物類、果汁抽出物類、果物フレーバー類等を用いることもできる。
【0015】
これらのヒドロキシカルボン酸は、1種以上を組み合せて本発明飲料中に含有させてもよくその含有量は0.005〜10.0重量%であり、0.01〜5.0重量%が特に好ましい。当該含有量が0.005重量%未満では、pH緩衝能が弱く、エピ体カテキン類の安定化効果が不十分となる。
【0016】
本発明の紅茶飲料に使用する紅茶としては、Camellia属、例えばC.sinensis、C.assaimica及びやぶきた種、又はそれらの雑種から得られる茶葉から発酵工程を経て製茶された紅茶が挙げられる。またダージリン、アッサム、スリランカなどの発酵茶の茶葉から水や熱水により抽出して得られるものでもよい。
【0017】
紅茶を抽出する方法については、攪拌抽出など従来の方法により行う。また抽出時に水に予めアスコルビン酸ナトリウムなどの有機酸又は有機酸塩類を添加してもよい。また煮沸脱気や窒素ガスなどの不活性ガスを通気して溶存酸素を除去しつついわゆる非酸化的雰囲気下で抽出する方法を併用してもよい。
【0018】
本発明の紅茶飲料は、紅茶に茶抽出物を添加して得られるものである。当該茶抽出物の添加により、非重合体カテキン類の濃度及びエピ体比率、更にガレート体率等を前記の範囲に調整することができる。
本発明の紅茶飲料に添加する茶抽出物は緑茶葉からの抽出液でもよいが、茶抽出物の濃縮物を水に溶解して用いても、緑茶葉からの抽出液と茶抽出物の濃縮物とを併用しても良い。ここでいう茶抽出物の濃縮物とは、茶葉を熱水もしくは水溶性有機溶媒により抽出された抽出物を濃縮したものであって、特開昭59−219384号公報、特開平4−20589号公報、特開平5−260907号公報、特開平5−306279号公報、特願2002−114355、特願2002−020415などに詳細に例示されている方法で調製したものをいう。市販品としては、三井農林(株)「ポリフェノン」、伊藤園(株)「テアフラン」、太陽化学(株)「サンフェノン」などが挙げられる。そのほか、カラム精製品及び化学合成品でも使用できる。ここでいう茶抽出物の濃縮物の形態としては、固体、水溶液、スラリー状など種々のものが挙げられる。茶抽出物を溶解する液体は水、非重合体カテキン類を少量含有する茶類が挙げられる。
【0019】
本発明の容器詰紅茶飲料には、茶由来の成分にあわせて、処方上添加して良い成分として、酸化防止剤、香料、各種エステル剤、無機酸類、無機酸塩類、無機塩類、色素類、乳化剤、保存料、調味料、甘味料、苦味調整剤、酸味料、果汁エキス類、pH調整剤、品質安定剤などの添加剤を単独あるいは併用して配合できる。
例えば甘味料としては、砂糖、ぶどう糖、果糖、異性化液糖、エリスリトール、グリチルリチン、ステビア、アスパラテーム、スクラロース、フラクトオリゴ糖、ガラクトオリゴ糖が挙げられる。本発明の容器詰紅茶飲料中に、0.0001〜10.0重量%含有するのがよい。
苦味調整剤としては、シクロデキストリンに代表される環状デキストリンが挙げられる。α−、β−、γ−シクロデキストリン及び、分岐α−、β−、γ−シクロデキストリンが使用できる。本発明中の容器詰紅茶飲料中に0.01〜1重量%含有するのがよい。
【0020】
本発明の容器詰紅茶飲料に使用される容器は、一般の飲料と同様にポリエチレンテレフタレートを主成分とする成形容器(いわゆるPETボトル)、金属缶、金属箔やプラスティックフィルムと複合された紙容器、ビンなどの通常の形態で提供することができる。ここでいう容器詰紅茶飲料とは希釈せずに飲用できるものをいう。
【0021】
また本発明の容器詰紅茶飲料は、例えば、金属缶のような容器に充填後、加熱殺菌できる場合にあっては食品衛生法に定められた殺菌条件で行なわれる。PETボトル、紙容器のようにレトルト殺菌できないものについては、あらかじめ上記と同等の殺菌条件、例えばプレート式熱交換器等で高温短時間殺菌後、一定の温度迄冷却して容器に充填する等の方法が採用される。
【0022】
【実施例】
非重合体カテキン類の測定
フィルター(0.8μm)で濾過した飲料を、島津製作所製、高速液体クロマトグラフ(形式SCL−10AVP)を用い、オクタデシル基導入液体クロマトグラフ用パックドカラム L−カラムTM ODS(4.6mmφ×250mm:財団法人 化学物質評価研究機構製)を装着し、カラム温度35℃でグラジエント法により行った。移動相A液は酢酸を0.1mol/l含有の蒸留水溶液、B液は酢酸を0.1mol/l含有のアセトニトリル溶液とし、試料注入量は20μl、UV検出器波長は280nmの条件で行った。
【0023】
体内吸収性の測定
(試験方法)
被験者は 20〜45 歳までの健常男子 3名を対象とした。採血3日前からは禁酒とし、その期間中は茶カテキン類及びポリフェノール類を多く含む食品の摂取を制限した。
食事は試験前日の昼食まで自由摂取としたが、夕食時には、熱量840kcal、蛋白質41g、脂質32g、糖質90gにコントロールさせた食事を被験者に摂取させ、午後6時以降から試験まで水以外の飲食を禁止した。同一被験者が本発明品と比較品とを飲用するクロスオーバー試験法を採用した。
試験は室温25℃の室内で行い、約1時間のコンディショニング時間を経てから飲用摂取前の血液をヘパリン処理した注射筒(10ml容)を用いて約8ml採血した。その後試験飲料を10分かけて350ml飲用させ、30分後、60分後、120分後に採血し、血中の遊離型カテキン類の量を定量した。
【0024】
(検体の前処理と血液中の非重合体カテキン類濃度の測定)
採血した血液の全血を4℃で15分間3000rpm/min.で遠心分離し上層の血漿を得る。この血漿250μlに1mol/lリン酸緩衝液5μl、蒸留水20μlと塩酸25μlを加え30秒間よく攪拌する。更に、メタノールを200μl加え30秒間攪拌する。これを5℃、20000×g、10分間にて遠心分離する。得られた上層をフィルターを装着した容器(ウルトラフリーCL)にとり、再度遠心分離(5℃、20000×g、10分間)を行い、得られた上層を測定溶液とする。
【0025】
HPLC−MS 測定条件
高速液体クロマトグラフィー装置HP1100(Agilent製)と質量分析計HP1100MSD(Agilent製)を用い下記の条件で測定する。
HPLC分析条件

Figure 0003638570
MS分析条件
イオン化法:API Electrospray
フラグメンター電圧:140V
ネブライザー:N2(50psi)
ドライガス:N2(10l/min、350℃)
モード:SIM(m/z)ネガティブ
検量線の作成
8種類のカテキン(試薬特級:シグマ)を5mg秤量し、0.2mol/l酢酸メタノール液5mlを加え、さらに水を加えて正確に10mlにし、これを標準母液(各500μg/ml)とする。この母液を用いそれぞれの成分の濃度が50ng/mlになるように、1mol/lリン酸緩衝液を用いリン酸濃度0.1mol/lになるよう希釈する。この標準溶液10μlをHPLCに注入し、得られたピーク面積と濃度より検量線を作成する。
【0026】
実施例1
表1に示す成分を混合して、所定の処理を行い容器詰紅茶飲料を製造した。
【0027】
【表1】
Figure 0003638570
【0028】
本発明品1及び比較品1の各容器詰紅茶飲料中の非重合体カテキン類の分析結果及び体内吸収性測定結果(血漿中の遊離型の非重合体カテキン類濃度:30分後、60分後、120分後に採血したサンプルのカテキン濃度3名分の平均値)を表中に示す。
【0029】
本発明品1はいずれも比較品に比べて血漿中に検出された遊離型の非重合体カテキン類量の増加がみられ、体内吸収性が増していることが示された。
【0030】
【発明の効果】
本発明の容器詰紅茶飲料は、非重合体カテキン類の同量の摂取においても、血液中への移行量が高く、吸収性に優れ、かつ味も良好であり健康増進に適した紅茶飲料である。[0001]
BACKGROUND OF THE INVENTION
The present invention relates to a packaged black tea beverage having a high blood migration rate of non-polymer catechins and a good taste.
[0002]
[Prior art]
Currently, a large amount of foods containing tea leaves as raw materials, including canned drinks and instant drinks, are being sold. On the other hand, non-polymer catechins contained in tea beverages such as green tea, black tea, oolong tea and the like have an inhibitory effect on cholesterol elevation (Japanese Patent Laid-Open No. 60-156614) and an inhibitory effect on α-amylase activity (Japanese Patent Laid-Open No. Hei 3- 133928), blood glucose elevation inhibiting action (Japanese Patent Laid-Open No. 4-253918), arteriosclerosis preventing action (Japanese Patent Laid-Open No. 4-352726), antioxidant action (Japanese Patent Publication No. 1-444234), antibacterial action (special Kaihei 2-276562), an anti-ulcer action (Japanese Patent Laid-Open No. 63-277628), and a physiological action such as a mutation suppressing action are reported.
[0003]
In order to more effectively express the physiological action of these non-polymer catechins, it is necessary to increase the intake of non-polymer catechins. In order to ingest a large amount of non-polymer catechins, a beverage form that is easy to ingest is desirable from the viewpoint of preference and marketability.
[0004]
However, in non-polymer catechins taken orally, only a small portion of non-polymer catechins are absorbed from the digestive tract, and some of them undergo conjugation reaction in the mucosal epithelial cells and pass through portal vein blood. It is transported to the liver, where it is further conjugated and partly enters the bloodstream in the free form and migrates to the peripheral tissue, but part is injected into the duodenum in the form of bile fluid secreted from the liver and enterohepatic circulation. In addition, it is known that it will eventually be excreted in the urine via the kidney (Chemistry and Biology, vol38, No 2, 104-114, 2000). Thus, simply increasing the content of non-polymer catechins in the beverage does not necessarily increase the blood transfer rate.
[0005]
[Problems to be solved by the invention]
An object of the present invention is to provide a tea beverage that increases the amount of non-polymer catechins that have been drunk into the blood, improves the utilization in the body, and has a good taste.
[0006]
[Means for Solving the Problems]
Therefore, the present inventor manufactured various black tea beverages and examined the relationship between the non-polymer catechins composition and the blood migration rate, and found that in the packaged black tea beverages containing non-polymer catechins at a high concentration. By controlling the ratio of epimeric catechins in non-polymer catechins, it is possible to further increase the amount of non-polymer catechins transferred to the blood when ingested while maintaining the same non-polymer catechin concentration. I found it.
[0007]
That is, the present invention provides 1) the following non-polymeric components (A) and (B):
A) Non-epimeric catechins (catechin + gallocatechin + catechin gallate + gallocatechin gallate)
(B) Epi-catechins (epicatechin + epigallocatechin + epicatechin gallate + epigallocatechin gallate)
Catechins are dissolved and contained, and the contents of the components (A) and (B) are the following (A) and (B):
(A) (A) + (B) = 0.1 to 0.3% by weight
(B) (B) / [(A) + (B)] = 0.5-0.95
The filling,
2) Hydroxycarboxylic acid or a salt thereof contains 0.005 to 10.0% by weight,
3) A packaged black tea beverage to which a tea extract is added, having a pH of 3.0 to 4.7.
[0008]
DETAILED DESCRIPTION OF THE INVENTION
Non-polymer catechins [(A) + (B)] as used in the present invention means catechin, gallocatechin, catechin gallate, and non-epimeric catechins of gallocatechin gallate (A), epicatechin, epigallocatechin, epi It is a general term for catechin gallate and epigallocatechin gallate together with epi-catechins (B).
[0009]
In the present invention, the non-polymer catechins are non-polymer catechins dissolved in water. When not dissolved, it is preferable that non-polymer catechins are dissolved since the absorbability in the body is physically lowered.
[0010]
The non-polymer catechins [(A) + (B)] are contained in the black tea beverage of the present invention in an amount of 0.1 to 0.3% by weight, preferably 0.1 to 0.25% by weight, more preferably 0. .1 to 0.2% by weight. If the concentration of non-polymer catechins is less than 0.1% by weight, a sufficient physiological effect cannot be obtained, and if it exceeds 0.3% by weight, the flavor becomes unfavorable.
[0011]
The non-polymer catechins in the black tea beverage of the present invention contain epi-catechins (B) in a weight ratio [(B) / (A) + (B)] of 0.5 to 0.95, preferably 0.6 to 0.9, more preferably 0.66 to 0.9 is included. When this ratio is less than 0.5, the blood non-polymer catechins ingestion rate is not sufficient.
[0012]
Epigallocatechin gallate, gallocatechin gallate, epicatechin gallate and catechin gallate (gallate form) in non-polymer catechins [(A) + (B)] are said to have strong physiological activity. Here, epigallocatechin gallate, gallocatechin gallate, epicatechin gallate and catechin gallate are contained in one or more kinds, but usually all are contained. Here, the weight% of the gallate body in the catechins [(A) + (B)] is called a gallate body ratio.
In the present invention, the percentage of gallate body is 45% by weight or more, more preferably 46 to 98% by weight, which increases the amount of non-polymer catechins transferred to the blood when ingested, resulting in physiological effects. It is strong and becomes more preferable as a health tea drink.
[0013]
The pH of the packaged black tea beverage of the present invention is preferably 3.0 to 4.7, particularly 3.3 to 4.5 at 25 ° C. in terms of taste and chemical stability of non-polymer catechins. . Non-polymerized catechins have a bitter and astringent taste, but when a sour component is added thereto, the bitter and astringent taste is alleviated. Moreover, isomerization (non-epimerization) of epimeric catechins due to heating and sterilization is suppressed by lowering the pH, and the amount of transferred blood increases.
[0014]
It is preferable to add a hydroxycarboxylic acid or a salt thereof to the black tea beverage of the present invention because the taste can be improved and the pH can be adjusted. As the hydroxycarboxylic acid, at least one selected from citric acid, succinic acid, itaconic acid, malic acid and tartaric acid is preferable from the viewpoint of taste. Here, examples of the salt include alkali metal salts such as sodium salt and potassium salt, and alkaline earth metal salts such as calcium salt and magnesium salt. In addition, fruit juices, fruit juice concentrates, fruit juice extracts, fruit flavors and the like containing these hydroxycarboxylic acids or salts thereof can also be used.
[0015]
These hydroxycarboxylic acids may be combined in one or more kinds and contained in the beverage of the present invention, and the content thereof is 0.005 to 10.0% by weight, particularly 0.01 to 5.0% by weight. preferable. When the content is less than 0.005% by weight, the pH buffering ability is weak, and the stabilization effect of epimeric catechins becomes insufficient.
[0016]
Examples of the black tea used in the black tea beverage of the present invention include black tea produced through a fermentation process from tea leaves obtained from the genus Camellia, for example, C. sinensis, C. assamica and Yabuki species, or hybrids thereof. Further, it may be obtained by extraction from fermented tea leaves such as Darjeeling, Assam, Sri Lanka with water or hot water.
[0017]
About the method of extracting black tea, it carries out by conventional methods, such as stirring extraction. Further, an organic acid such as sodium ascorbate or an organic acid salt may be added to water in advance during extraction. Moreover, you may use together the method of extracting in so-called non-oxidative atmosphere, ventilating inert gas, such as boiling deaeration and nitrogen gas, and removing dissolved oxygen.
[0018]
The black tea beverage of the present invention is obtained by adding a tea extract to black tea. By adding the tea extract, the concentration of non-polymer catechins and the epi form ratio, and the gallate form ratio can be adjusted to the above ranges.
The tea extract to be added to the black tea beverage of the present invention may be an extract from green tea leaves, or even if the concentrate of tea extract is dissolved in water and used, the extract from green tea leaves and the concentration of tea extract are used. You may use together. The concentrate of tea extract referred to here is a concentrate obtained by concentrating an extract obtained by extracting tea leaves with hot water or a water-soluble organic solvent, and is disclosed in JP-A-59-219384 and JP-A-4-20589. It is prepared by the method exemplified in detail in Japanese Patent Laid-Open No. 5-260907, Japanese Patent Laid-Open No. 5-306279, Japanese Patent Application No. 2002-114355, Japanese Patent Application No. 2002-020415, and the like. Examples of commercially available products include “Polyphenone”, Mitsui Norin Co., Ltd., “Theafranc”, ITO EN Co., Ltd., and “Sunphenon”, Taiyo Kagaku Co., Ltd. In addition, it can also be used in column purified products and chemically synthesized products. The form of the concentrate of the tea extract here includes various forms such as a solid, an aqueous solution, and a slurry. Examples of the liquid that dissolves the tea extract include water and teas containing a small amount of non-polymer catechins.
[0019]
In the packaged black tea beverage of the present invention, as ingredients that may be added in accordance with the ingredients derived from tea, antioxidants, fragrances, various ester agents, inorganic acids, inorganic acid salts, inorganic salts, pigments, Additives such as emulsifiers, preservatives, seasonings, sweeteners, bitterness adjusters, acidulants, fruit juice extracts, pH adjusters, and quality stabilizers can be used alone or in combination.
Examples of sweeteners include sugar, glucose, fructose, isomerized liquid sugar, erythritol, glycyrrhizin, stevia, aspartame, sucralose, fructooligosaccharide, and galactooligosaccharide. It is good to contain 0.0001-10.0 weight% in the container-packed black tea beverage of this invention.
Examples of the bitterness adjusting agent include cyclic dextrin typified by cyclodextrin. α-, β-, γ-cyclodextrin and branched α-, β-, γ-cyclodextrin can be used. It is good to contain 0.01 to 1weight% in the container-packed black tea beverage in this invention.
[0020]
The container used for the container-packed black tea beverage of the present invention is a molded container mainly composed of polyethylene terephthalate (so-called PET bottle), a metal can, a paper container combined with a metal foil or a plastic film, like a general beverage, It can be provided in a conventional form such as a bottle. The container-packed black tea beverage here refers to a beverage that can be drunk without dilution.
[0021]
Moreover, the container-packed black tea drink of this invention is performed on the sterilization conditions prescribed | regulated to the food hygiene law, for example, when it can heat-sterilize after filling a container like a metal can. For PET bottles and paper containers that cannot be sterilized by retort, sterilize under the same conditions as above, for example, after sterilizing at high temperature and short time with a plate heat exchanger, etc. The method is adopted.
[0022]
【Example】
Measurement of non-polymer catechins Packed column for octadecyl group-introduced liquid chromatograph using a high-performance liquid chromatograph (model SCL-10AVP) manufactured by Shimadzu Corporation for the beverage filtered with a filter (0.8 μm) L -Column TM ODS (4.6 mmφ x 250 mm: manufactured by Chemical Substance Evaluation Research Organization) was attached, and the gradient was performed at a column temperature of 35 ° C. The mobile phase A solution was a distilled aqueous solution containing 0.1 mol / l acetic acid, the B solution was an acetonitrile solution containing 0.1 mol / l acetic acid, the sample injection volume was 20 μl, and the UV detector wavelength was 280 nm. .
[0023]
Measurement of absorption in the body
(Test method)
The subjects were three healthy boys aged 20 to 45 years. Alcohol was prohibited for 3 days before blood collection, and the intake of foods rich in tea catechins and polyphenols was restricted during that period.
Meals were taken freely until lunch the day before the test, but at dinner, subjects were allowed to eat a diet controlled by calorie 840 kcal, protein 41 g, lipid 32 g, and carbohydrates 90 g. Banned. A crossover test method in which the same subject drinks the product of the present invention and the comparative product was adopted.
The test was performed at room temperature of 25 ° C., and after about 1 hour of conditioning time, about 8 ml of blood was collected using a syringe (10 ml volume) in which blood before drinking was heparinized. Thereafter, 350 ml of the test beverage was drunk over 10 minutes, blood was collected after 30 minutes, 60 minutes, and 120 minutes, and the amount of free catechins in the blood was quantified.
[0024]
(Pretreatment of specimen and measurement of concentration of non-polymer catechins in blood)
The whole blood collected was collected at 3000 rpm / min for 15 minutes at 4 ° C. Centrifuge to obtain the upper plasma layer. To 250 μl of this plasma, add 5 μl of 1 mol / l phosphate buffer, 20 μl of distilled water and 25 μl of hydrochloric acid, and stir well for 30 seconds. Further, 200 μl of methanol is added and stirred for 30 seconds. This is centrifuged at 20000 × g for 10 minutes at 5 ° C. The obtained upper layer is put into a container (Ultra Free CL) equipped with a filter, and centrifuged again (5 ° C., 20000 × g, 10 minutes), and the obtained upper layer is used as a measurement solution.
[0025]
HPLC-MS Measurement conditions Measurement is performed under the following conditions using a high performance liquid chromatography apparatus HP1100 (manufactured by Agilent) and a mass spectrometer HP1100MSD (manufactured by Agilent).
HPLC analysis conditions
Figure 0003638570
MS analysis conditions Ionization method: API Electrospray
Fragmentor voltage: 140V
Nebulizer: N2 (50 psi)
Dry gas: N2 (10 l / min, 350 ° C.)
Mode: SIM (m / z) negative
Preparation of calibration curve Weigh 5 mg of 8 types of catechins (reagent grade: Sigma), add 5 ml of 0.2 mol / l acetic acid methanol solution, and add water to make exactly 10 ml. ). The mother liquor is used to dilute the phosphoric acid concentration to 0.1 mol / l using a 1 mol / l phosphate buffer so that the concentration of each component is 50 ng / ml. 10 μl of this standard solution is injected into HPLC, and a calibration curve is prepared from the obtained peak area and concentration.
[0026]
Example 1
The components shown in Table 1 were mixed and subjected to a predetermined treatment to produce a containerized black tea beverage.
[0027]
[Table 1]
Figure 0003638570
[0028]
Results of analysis of non-polymer catechins in each of the packaged black tea beverages of the present invention product 1 and comparative product 1 and measurement results of absorption in the body (concentration of free non-polymer catechins in plasma: 30 minutes later, 60 minutes) Thereafter, the average value of 3 catechin concentrations of samples collected 120 minutes later is shown in the table.
[0029]
The product of the present invention 1 showed an increase in the amount of free non-polymer catechins detected in plasma compared to the comparative product, indicating that the absorbability in the body was increased.
[0030]
【The invention's effect】
The packaged black tea beverage of the present invention is a black tea beverage that is suitable for promoting health, having a high transfer amount into the blood, excellent absorbability and good taste even when ingesting the same amount of non-polymer catechins. is there.

Claims (3)

1)次の非重合体成分(A)及び(B):
(A)非エピ体カテキン類(カテキン+ガロカテキン+カテキンガレート+ガロカテキンガレート)
(B)エピ体カテキン類(エピカテキン+エピガロカテキン+エピカテキンガレート+エピガロカテキンガレート)
のカテキン類を溶解して含有し、当該成分(A)及び(B)の含有量が次の(イ)及び(ロ)、
(イ)(A)+(B)=0.1〜0.3重量%、
(ロ)(B)/[(A)+(B)]=0.5〜0.95
を満たし、
2)ヒドロキシカルボン酸又はそれらの塩類 0.005〜10.0重量%を含有し、
3)pHが3.0〜4.7である、茶抽出物を添加した容器詰紅茶飲料。
1) The following non-polymeric components (A) and (B):
(A) Non-epimeric catechins (catechin + gallocatechin + catechin gallate + gallocatechin gallate)
(B) Epi-catechins (epicatechin + epigallocatechin + epicatechin gallate + epigallocatechin gallate)
Catechins are dissolved and contained, and the contents of the components (A) and (B) are the following (A) and (B):
(A) (A) + (B) = 0.1 to 0.3% by weight,
(B) (B) / [(A) + (B)] = 0.5-0.95
The filling,
2) Hydroxycarboxylic acid or a salt thereof contains 0.005 to 10.0% by weight,
3) Containerized black tea beverage to which a tea extract is added, having a pH of 3.0 to 4.7.
ヒドロキシカルボン酸が、クエン酸、コハク酸、イタコン酸、リンゴ酸及び酒石酸から選ばれる1種以上である請求項1記載の容器詰紅茶飲料。The packaged black tea beverage according to claim 1, wherein the hydroxycarboxylic acid is at least one selected from citric acid, succinic acid, itaconic acid, malic acid and tartaric acid. 紅茶の抽出液に緑茶抽出物の濃縮物を添加したものである請求項1又は2記載の容器詰紅茶飲料。The container-packed black tea beverage according to claim 1 or 2, wherein a concentrate of green tea extract is added to the black tea extract.
JP2002143743A 2002-05-17 2002-05-17 Containerized tea beverage Expired - Fee Related JP3638570B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2002143743A JP3638570B2 (en) 2002-05-17 2002-05-17 Containerized tea beverage

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2002143743A JP3638570B2 (en) 2002-05-17 2002-05-17 Containerized tea beverage

Publications (2)

Publication Number Publication Date
JP2003333989A JP2003333989A (en) 2003-11-25
JP3638570B2 true JP3638570B2 (en) 2005-04-13

Family

ID=29703661

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2002143743A Expired - Fee Related JP3638570B2 (en) 2002-05-17 2002-05-17 Containerized tea beverage

Country Status (1)

Country Link
JP (1) JP3638570B2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007066744A1 (en) 2005-12-06 2007-06-14 Ito En, Ltd. Method of improving absorbability of epigallocatechin, food, drink and food/drink material using the same and method of producing the same

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1217583C (en) * 2000-11-17 2005-09-07 花王株式会社 Packaged beverages
CN100518528C (en) 2003-09-26 2009-07-29 花王株式会社 Packaged beverage
JP3766670B2 (en) * 2003-12-16 2006-04-12 花王株式会社 Container drink
JP4884003B2 (en) * 2005-12-27 2012-02-22 花王株式会社 Container oolong tea drink
JP5118334B2 (en) * 2006-11-20 2013-01-16 三井農林株式会社 High concentration black tea containing polyphenols
WO2008078361A1 (en) * 2006-12-22 2008-07-03 Kao Corporation Black tea drink packed in container
EP2098121B1 (en) 2006-12-22 2013-09-18 Kao Corporation Green tea drink packed in container
WO2008078360A1 (en) * 2006-12-22 2008-07-03 Kao Corporation Non-tea drink packed in container
JP2008178401A (en) * 2006-12-27 2008-08-07 Kao Corp Packaged beverage
JP5297649B2 (en) * 2006-12-27 2013-09-25 花王株式会社 Container drink
JP4999084B2 (en) * 2007-06-14 2012-08-15 三井農林株式会社 Instant powder tea
JP5517421B2 (en) * 2007-08-03 2014-06-11 花王株式会社 Container drink
EP2186418A4 (en) * 2007-08-30 2011-11-16 Kao Corp Instant powder drink
JP5550274B2 (en) * 2009-07-17 2014-07-16 花王株式会社 Container drink
WO2011042958A1 (en) 2009-10-06 2011-04-14 森永製菓株式会社 Polyphenol compound absorption promoter and utilization of same
JP5610736B2 (en) * 2009-10-06 2014-10-22 森永製菓株式会社 Pharmaceutical composition for promoting absorption of polyphenol compounds, method for producing food / beverage products or food / beverage materials containing polyphenol compounds, and food / beverage products or food / beverage materials containing polyphenol compounds
JP5760429B2 (en) * 2009-12-22 2015-08-12 大正製薬株式会社 Liquid composition

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007066744A1 (en) 2005-12-06 2007-06-14 Ito En, Ltd. Method of improving absorbability of epigallocatechin, food, drink and food/drink material using the same and method of producing the same

Also Published As

Publication number Publication date
JP2003333989A (en) 2003-11-25

Similar Documents

Publication Publication Date Title
JP3638588B2 (en) Containerized tea beverage
JP3638570B2 (en) Containerized tea beverage
JP3403400B1 (en) Packaged beverage
TWI454222B (en) Production process of purified green tea extract
TWI451844B (en) Production process of purified green tea extract
TWI411403B (en) Production process of purified green tea extract
JP4745784B2 (en) Purified green tea extract
JP4884003B2 (en) Container oolong tea drink
JP5399864B2 (en) Purified tea extract
KR20060131759A (en) Package drink
TWI439231B (en) Method for producing purified substances of green tea extract
JP4800779B2 (en) Method for producing purified green tea extract
JP4751204B2 (en) Method for producing purified green tea extract
JP5366771B2 (en) Purified green tea extract
JP2009247215A (en) Bottled drink
JP4247178B2 (en) Method for producing purified green tea extract
JP4768534B2 (en) Containerized green tea beverage
JP4383337B2 (en) High concentration catechin-containing container-packed oolong tea drink
JP2011015632A (en) Bitter taste inhibitor
JP5366739B2 (en) Containerized acidic black tea beverage
JP3638560B2 (en) Production method of semi-fermented tea beverage and fermented tea beverage
JP2015000054A (en) Container-packed beverage
JP2011072219A (en) Packaged beverage
JP4119829B2 (en) Green tea bottled beverage
JP5550274B2 (en) Container drink

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20040510

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20041227

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20050105

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20050111

R151 Written notification of patent or utility model registration

Ref document number: 3638570

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R151

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20090121

Year of fee payment: 4

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20090121

Year of fee payment: 4

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20100121

Year of fee payment: 5

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20110121

Year of fee payment: 6

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20110121

Year of fee payment: 6

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20120121

Year of fee payment: 7

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20120121

Year of fee payment: 7

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20130121

Year of fee payment: 8

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20130121

Year of fee payment: 8

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20140121

Year of fee payment: 9

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees